Vaccines in the treatment of multiple myeloma;Vakcíny v léčbé mnohočetného myelomu

Klinicka Onkologie

Volumn 15, Issue SUPPL., 2002, Pages 44-47

  Buchler T ^a   Musilova R ^a   Kovarova L ^a   Hajek R ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Dendritic cells; Idiotype; Immunotherapy; Multiple myeloma; Vaccination

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MONOCLONAL ANTIBODY; PARAPROTEIN;

B CELL LEUKEMIA; CELL CLONE; CELL SURFACE; DENDRITIC CELL; DRUG CONJUGATION; HUMAN; IMMUNE RESPONSE; MULTIPLE MYELOMA; PLASMA CELL; SHORT SURVEY; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; VACCINATION;

EID: 0036033895     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (47)

1. Barratt-Boyes SM, Watkins SC, Finn OJ. Migration of cultured chimpanzee dendritic cells following intravenous and subcutaneous injection. Adv Exp Med Biol. 1997;417:71-5
2. Barratt-Boyes SM, Watkins SC, Finn OJ: In vivo migration of dendritic cells differentiated in vitro: A chimpanzee model. J Immunol 1997, 158: 4543-4547.
3. Bender A, Sapp M, Schuler G, Steinman RM, Bhardwaj N: Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods 1996, 196: 121-135.
4. Bergenbrant S, Yi Q, Österborg A, et al.: Modulation of anti-idiotypic immune response by immunization with the autologous M-component protein in multiple myeloma patients. Brit J Haematol 1996, 92: 840-846.
5. Bianchi A, Massaia M. Idiotypic vaccination in B-cell malignancies. Mol Med Today 1997;3:435-41.
6. Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol 2001;29:1247-1255.
7. Büchler T, Hájek R, Bourková L, et al.. Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations. Vaccine 2002 (v tisku).
8. Büchler T, Hájek R. Dendritic cell vaccines in the treatment of multiple myeloma - Advances and limitations. Medical Oncology 2002 (v tisku).
9. Cull G, Durrant L, Stainer C, Haynes A, Russell N. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma. Br J Haematol 1999;107:648-655.
10. Finkelman FD, Lees A, Birnbaum R, Gause WC, Morris SC. Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion. J Immunol. 1996 Aug 15;157(4):1406-14.
11. Grohmann U, Bianchi R, Ayroldi E, et al. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J Immunol. 1997 Apr 15;158(8):3593-602.
12. Hájek R, Adam Z, Křivanová A, et al.: Current role of immunotherapy in multiple myeloma. Acta Medica Austriaca 1998, 25, 3:79-86.
13. Hajek R, Butch AW. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med Oncol. 2000 Feb; 17(1):2-15.
14. Hart DNJ.: Dendritic cells: Unique leukocyte populations which control the primary immune response. Blood 1997, 90:3245-3287.
15. Hsu FJ, Benike C, Fagnoni F, et al.: Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med 1996;2:52-58.
16. Ingulli E, Mondino A, Khoruts A, Jenkins MK. In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med. 1997 Jun 16;185(12):2133-41.
17. Ishisaka T, Nevin B, Valone FH, Kothari SS, Peshwa MV. Comparison of Cryopreserved Versus Fresh Formulation of Idiotype-Loaded Autologous Dendritic Cell Vaccine. Program and Abstracts of the 43rd Annual Meeting of the American Society of Hematology; December 7-11, 2001; Orlando, Florida. Abstract 4989.
18. Kamath AT, Pooley J, O'Keeffe MA, et al. The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol. 2000 Dec 15;165(12):6762-70.
19. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med. 1992 Oct 22;327(17):1209-15.
20. Kwak LW, Taub DD, Duffey PL, et al.: Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 1995, 345:1016-1020.
21. Kwak LW, Thielemans K, Massaia M: Idiotypic Vaccionation as Therapy for Multiple Myeloma. Seminar Hematol 1999, 6, 1 (Suppl 3): 34-37.
22. Lim SH, Bailey-Wood R. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999;83:215-22.
23. Lim SH, Bailey-Wood R: Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma. Int J Cancer 1999;83:215-222.
24. Lincoln CK, Gabridge MG. Cell culture contamination: Sources, consequences, prevention, and elimination. Methods Cell Biol. 1998;57:49-65.
25. Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000;6:621-627
26. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci U S A 1972;69:1540-4.
27. MacKenzie M, Strang G, Peshwa M, Sopapan J, Valone F: Phase I/II trial of immunotherapy with idiotype-loaded autologous dendritic cells (APC8020) for refractory multiple myeloma. Blood 1998;92 (Suppl 1): abstr 108a.
28. Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. Blood. 1999 Jul 15;94(2):673-83.
29. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med. 1995 Dec;1 (12):1297-302.
30. Österborg A, Masucci M, Bergenbrant S, Holm G, Lefvert AK, Mellstedt H. Generation of T cell clones binding F(ab')2 fragments of the idiotypic immunoglobulin in patients with monoclonal gammopathy. Cancer Immunol Immunother 1991;34:157-62.
31. Österborg A, Yi Q, Henriksson L, et al. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses. Blood 1998, 91:2459-2466.
32. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study. Blood 1999; 93:2411-2419
33. Romani N, Koide S, Crowley M, et al.: Presentation of exogenous protein antigens by dendritic cells to T cell clones. Intact protein is presented best by immature, epidermal Langerhans cells. J Exp Med 1989, 169: 1169-1178.
34. Romani N, Reider D, Heuer M, et al.: Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods 1996, 196:137-151.
35. Roskrow MA, Dilloo D, Suzuki N, Zhong W, Rooney CM, Brenner MK. Autoimmune disease induced by dendritic cell immunization against leukemia. Leuk Res. 1999 Jun;23(6):549-57.
36. Ruffini PA, Kwak LW. Immunotherapy of multiple myeloma. Semin Hematol 2001;38:260-7.
37. Sallusto F, Cella M, Daniel C, Lanzavecchia A: Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products [see comments]. J Exp Med 1995, 182:389-400.
38. Stacey A, Doyle A. Routine testing of cell cultures and their products for mycoplasma contamination. Methods Mol Biol. 1997;75:305-11.
39. Steinman RM.: Dendritic cells and immune-based therapies. Exp Hematol 1996, 24:859-862
40. Timmerman JM, Levy R. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J Immunol 2000;164:4797-4803.
41. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects. Br J Haematol 2000;108:805-816
42. Treon SP, Anderson KC. The use of rituximab in the treatment of malignant and nonmalignant plasma cell disorders. Semin Oncol 2000;27 (Suppl 12):79-85.
43. Tricot G, Vesole DH, Jagannath S, et al.: Graft-versus-myeloma-effect: Proof and principle. Blood 1996, 87:1196-1197.
44. Wen YJ, Barlogie B, Yi Q. Idiotype-specific cytotoxic T lymphocytes in multiple myeloma: Evidence for their capacity to lyse autologous primary tumor cells. Blood 2001 15;97:1750-5.
45. Wen YJ, Ling M, Bailey-Wood R, Lim SH: Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma. Clinical Cancer Research 1998, 4: 957-962.
46. Yang S, Darrow TL, Vervaert CE, Seigler HF: Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. Cellular Immunol 1997, 179:84-95.
47. Zeis M, Zunkel T, Steinmann J, Schmitz N, Uharek L. Enhanced antitumoral effectiveness of idiotype vaccination induced by the administration of Flt3 ligand combined with interleukin 2 against a murine myeloma. Br J Haematol 2002;117:93-102.